NL8800805A - Gesubstitueerde 1,3-dioxolaan en 1,3-dioxaanderivaten, werkwijzen voor de bereiding van deze derivaten en hun toepassing. - Google Patents
Gesubstitueerde 1,3-dioxolaan en 1,3-dioxaanderivaten, werkwijzen voor de bereiding van deze derivaten en hun toepassing. Download PDFInfo
- Publication number
- NL8800805A NL8800805A NL8800805A NL8800805A NL8800805A NL 8800805 A NL8800805 A NL 8800805A NL 8800805 A NL8800805 A NL 8800805A NL 8800805 A NL8800805 A NL 8800805A NL 8800805 A NL8800805 A NL 8800805A
- Authority
- NL
- Netherlands
- Prior art keywords
- tolyl
- dioxolane
- formula
- compound
- butyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical class C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 title description 3
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical class C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- KONLOUNOGLJAIE-UHFFFAOYSA-N 2-tert-butyl-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C(C)(C)C)OCCO1 KONLOUNOGLJAIE-UHFFFAOYSA-N 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 239000003472 antidiabetic agent Substances 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940125708 antidiabetic agent Drugs 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- JFSURDQTNPEVAL-UHFFFAOYSA-N 2-(1-methylcyclohexyl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C2(C)CCCCC2)OCCO1 JFSURDQTNPEVAL-UHFFFAOYSA-N 0.000 claims description 2
- KMLAMOMPQVOCBA-UHFFFAOYSA-N 2-(1-methylcyclopropyl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C2(C)CC2)OCCO1 KMLAMOMPQVOCBA-UHFFFAOYSA-N 0.000 claims description 2
- GVSIMOFSQGJJFE-UHFFFAOYSA-N 2-(2-adamantyl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C12C(C3CC(CC(C1)C3)C2)C2(OCCO2)C2=CC=C(C=C2)C GVSIMOFSQGJJFE-UHFFFAOYSA-N 0.000 claims description 2
- CEVJOQXUFOIJNG-UHFFFAOYSA-N 2-(2-methylpentan-2-yl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C=1C=C(C)C=CC=1C1(C(C)(C)CCC)OCCO1 CEVJOQXUFOIJNG-UHFFFAOYSA-N 0.000 claims description 2
- LUFBGYMZEQHSPV-UHFFFAOYSA-N 2-(3-ethylpentan-3-yl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C=1C=C(C)C=CC=1C1(C(CC)(CC)CC)OCCO1 LUFBGYMZEQHSPV-UHFFFAOYSA-N 0.000 claims description 2
- PUGWYZCAGAHQNO-UHFFFAOYSA-N 2-tert-butyl-2-(4-methylphenyl)-1,3-dioxane Chemical compound C1=CC(C)=CC=C1C1(C(C)(C)C)OCCCO1 PUGWYZCAGAHQNO-UHFFFAOYSA-N 0.000 claims description 2
- KAQZZSGJCQCQDU-UHFFFAOYSA-N 2-tert-butyl-4,5-dimethyl-2-(4-methylphenyl)-1,3-dioxolane Chemical compound O1C(C)C(C)OC1(C(C)(C)C)C1=CC=C(C)C=C1 KAQZZSGJCQCQDU-UHFFFAOYSA-N 0.000 claims description 2
- STBSQPTWFWISDM-UHFFFAOYSA-N 2-tert-butyl-4-methyl-2-(4-methylphenyl)-1,3-dioxolane Chemical compound O1C(C)COC1(C(C)(C)C)C1=CC=C(C)C=C1 STBSQPTWFWISDM-UHFFFAOYSA-N 0.000 claims description 2
- ZBOOOHNXFIMWRE-UHFFFAOYSA-N 2-tert-butyl-5,5-dimethyl-2-(4-methylphenyl)-1,3-dioxane Chemical compound C1=CC(C)=CC=C1C1(C(C)(C)C)OCC(C)(C)CO1 ZBOOOHNXFIMWRE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- ZRYUJKCBKVZXPJ-UHFFFAOYSA-N 2-(2-methylbutan-2-yl)-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C=1C=C(C)C=CC=1C1(C(C)(C)CC)OCCO1 ZRYUJKCBKVZXPJ-UHFFFAOYSA-N 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- -1 polyoxyethylene stearate Polymers 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 150000000093 1,3-dioxanes Chemical class 0.000 description 2
- ZYWGAHRBGCEFAO-UHFFFAOYSA-N 2,2-dimethyl-1-(4-methylphenyl)propan-1-one Chemical compound CC1=CC=C(C(=O)C(C)(C)C)C=C1 ZYWGAHRBGCEFAO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- GLIVXMCIDJSIMJ-UHFFFAOYSA-N (1-methylcyclopropyl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1(C)CC1 GLIVXMCIDJSIMJ-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CUBXMCHSJORTEN-UHFFFAOYSA-N 2,2-diethyl-1-(4-methylphenyl)butan-1-one Chemical compound C1(=CC=C(C=C1)C(=O)C(CC)(CC)CC)C CUBXMCHSJORTEN-UHFFFAOYSA-N 0.000 description 1
- MKMWDDZSCAQSOQ-UHFFFAOYSA-N 2,2-dimethyl-1-(4-methylphenyl)butan-1-one Chemical compound CCC(C)(C)C(=O)C1=CC=C(C)C=C1 MKMWDDZSCAQSOQ-UHFFFAOYSA-N 0.000 description 1
- FDSAYCYOKLMSHG-UHFFFAOYSA-N 2,2-dimethyl-1-(4-methylphenyl)pentan-1-one Chemical compound C1(=CC=C(C=C1)C(=O)C(CCC)(C)C)C FDSAYCYOKLMSHG-UHFFFAOYSA-N 0.000 description 1
- WGTYXBCLGNWBEN-UHFFFAOYSA-N 2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1OCCO1 WGTYXBCLGNWBEN-UHFFFAOYSA-N 0.000 description 1
- UWWGSXYTVPACKO-UHFFFAOYSA-N 2-tert-butyl-2-(3-methylphenyl)-1,3-dioxolane Chemical compound CC1=CC=CC(C2(OCCO2)C(C)(C)C)=C1 UWWGSXYTVPACKO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- TXNJMRAUGLOGEY-UHFFFAOYSA-N bis[4-methyl-3-(1-methylcyclohexyl)phenyl]methanone Chemical compound CC1(CCCCC1)C1=C(C=CC(=C1)C(=O)C1=CC(=C(C=C1)C)C1(CCCCC1)C)C TXNJMRAUGLOGEY-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3411887A | 1987-04-01 | 1987-04-01 | |
| US3411887 | 1987-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8800805A true NL8800805A (nl) | 1988-11-01 |
Family
ID=21874422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8800805A NL8800805A (nl) | 1987-04-01 | 1988-03-30 | Gesubstitueerde 1,3-dioxolaan en 1,3-dioxaanderivaten, werkwijzen voor de bereiding van deze derivaten en hun toepassing. |
Country Status (18)
| Country | Link |
|---|---|
| JP (1) | JPS63277672A (fr) |
| KR (1) | KR880012224A (fr) |
| AU (1) | AU1400788A (fr) |
| BE (1) | BE1000783A3 (fr) |
| DE (1) | DE3810874A1 (fr) |
| DK (1) | DK179288A (fr) |
| ES (1) | ES2011831A6 (fr) |
| FR (1) | FR2613226B1 (fr) |
| GB (1) | GB2202849A (fr) |
| GR (1) | GR880100196A (fr) |
| HU (1) | HUT50156A (fr) |
| IL (1) | IL85920A0 (fr) |
| IT (1) | IT1219895B (fr) |
| LU (1) | LU87176A1 (fr) |
| NL (1) | NL8800805A (fr) |
| PT (1) | PT87127B (fr) |
| SE (1) | SE8801166L (fr) |
| ZA (1) | ZA882350B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8701961D0 (en) * | 1987-01-29 | 1987-03-04 | Unilever Plc | Perfumery materials |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3235589A1 (de) * | 1982-09-25 | 1984-03-29 | Hoechst Ag, 6230 Frankfurt | Benzylether von phenol-mannich-basen, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen, zwischenprodukte und verfahren zu deren herstellung |
-
1988
- 1988-03-23 LU LU87176A patent/LU87176A1/fr unknown
- 1988-03-28 BE BE8800360A patent/BE1000783A3/fr not_active IP Right Cessation
- 1988-03-28 FR FR888804153A patent/FR2613226B1/fr not_active Expired
- 1988-03-29 GB GB08807503A patent/GB2202849A/en not_active Withdrawn
- 1988-03-29 GR GR880100196A patent/GR880100196A/el unknown
- 1988-03-29 SE SE8801166A patent/SE8801166L/xx not_active Application Discontinuation
- 1988-03-30 IT IT47797/88A patent/IT1219895B/it active
- 1988-03-30 AU AU14007/88A patent/AU1400788A/en not_active Abandoned
- 1988-03-30 NL NL8800805A patent/NL8800805A/nl not_active Application Discontinuation
- 1988-03-30 ES ES8801002A patent/ES2011831A6/es not_active Expired - Lifetime
- 1988-03-30 HU HU881581A patent/HUT50156A/hu unknown
- 1988-03-30 KR KR1019880003491A patent/KR880012224A/ko not_active Withdrawn
- 1988-03-30 DE DE3810874A patent/DE3810874A1/de not_active Withdrawn
- 1988-03-30 IL IL85920A patent/IL85920A0/xx unknown
- 1988-03-30 PT PT87127A patent/PT87127B/pt not_active IP Right Cessation
- 1988-03-30 DK DK179288A patent/DK179288A/da not_active Application Discontinuation
- 1988-03-31 ZA ZA882350A patent/ZA882350B/xx unknown
- 1988-03-31 JP JP63081182A patent/JPS63277672A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA882350B (en) | 1989-12-27 |
| BE1000783A3 (fr) | 1989-04-04 |
| GB2202849A (en) | 1988-10-05 |
| FR2613226B1 (fr) | 1989-09-15 |
| DE3810874A1 (de) | 1988-10-20 |
| DK179288D0 (da) | 1988-03-30 |
| GB8807503D0 (en) | 1988-05-05 |
| ES2011831A6 (es) | 1990-02-16 |
| IT8847797A0 (it) | 1988-03-30 |
| KR880012224A (ko) | 1988-11-26 |
| SE8801166D0 (sv) | 1988-03-29 |
| GR880100196A (el) | 1989-01-31 |
| DK179288A (da) | 1988-10-02 |
| IL85920A0 (en) | 1988-09-30 |
| PT87127A (pt) | 1988-04-01 |
| PT87127B (pt) | 1992-07-31 |
| HUT50156A (en) | 1989-12-28 |
| AU1400788A (en) | 1988-10-06 |
| LU87176A1 (fr) | 1988-11-17 |
| SE8801166L (sv) | 1988-10-02 |
| FR2613226A1 (fr) | 1988-10-07 |
| IT1219895B (it) | 1990-05-24 |
| JPS63277672A (ja) | 1988-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0017195B1 (fr) | Dérivés de cyclohexane-1,3-diones substitués en positions 2 et 5, procédé pour leur préparation et composition pharmaceutique les contenant | |
| US3174901A (en) | Process for the oral treatment of diabetes | |
| JPH07502487A (ja) | 血糖低下性チアゾリジンジオンとその中間体 | |
| NL8800805A (nl) | Gesubstitueerde 1,3-dioxolaan en 1,3-dioxaanderivaten, werkwijzen voor de bereiding van deze derivaten en hun toepassing. | |
| US3923994A (en) | Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity | |
| FR2640271A1 (fr) | Nouveaux derives de l'adenosine, leur preparation et leur utilisation comme medicaments | |
| NL8101987A (nl) | De verbinding 4-amino-1-beta-d-ribofuranosyl-1h-imidazo/4.5-c/-pyridine of een farmaceutisch aanvaardbaar zuuradditiezout daarvan; farmaceutisch preparaat. | |
| JPS61275275A (ja) | 1,3−ジチオ−ル−2−イリデン誘導体 | |
| US3953601A (en) | Dibenzothiophene derivatives as serum lipid lowering agents | |
| EP0534655B1 (fr) | Thiazolidine-2,4-diones pour le traitement de l'hypertension | |
| US4320135A (en) | Inhibiting growth hormone secretion with 5,5-substituted hydantoin derivatives | |
| US4801589A (en) | Method for suppressing the immune response | |
| US3968247A (en) | Substituted or unsubstituted p-alkanoyl toluenes as anti-diabetic agents | |
| KR950003499B1 (ko) | 1,3,5-트리티안 유도체 | |
| US3941888A (en) | Substituted or unsubstituted p-alkanoyl toluenes as hypolipidemics | |
| FR2605006A1 (fr) | Derives du 5-fluorouracile, procede pour leur preparation, composition anticancereuse les contenant et leur utilisation pour la preparation d'une composition destinee au traitement d'un cancer | |
| US3222365A (en) | 4-halophenyl-2-alkyl-1(2)-phthalazinones | |
| US3562256A (en) | 1,3-dialkyl-5-(substituted arylsulfonyl)-tetrahydro-1,3,5-triazine-4-thiones | |
| US4057630A (en) | Antiarthritic compositions comprising bis-coordinated gold(1+) salts and methods of producing antiarthritic activity | |
| JPS6029693B2 (ja) | 1−オキソ−2,2−ジ置換−5−インダニロキシアルカノイツクアシツドの製法 | |
| EP0455830A1 (fr) | Medicament contenant un derive de dioxyde de thiazine | |
| JPH0256424A (ja) | 肝疾患治療剤 | |
| US3821378A (en) | 2-amino-4,6-diphenethylamino-s-triazine as active serum cholesterol lowering agent | |
| US4093719A (en) | Antiarthritic compositions comprising bis[(trialkyl-phosphine)gold(I)]sulfides and methods of producing antiarthritic activity | |
| JPS59164330A (ja) | ポリシルセスキオキサン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |